InvestorsHub Logo
Followers 4054
Posts 151767
Boards Moderated 3
Alias Born 08/05/2009

Re: Golden Cross post# 296

Friday, 12/08/2023 3:02:57 PM

Friday, December 08, 2023 3:02:57 PM

Post# of 407
Casgevy, developed by partners Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), and bluebird bio's (BLUE.) Lyfgenia were approved for people aged 12 years and older.
https://www.reuters.com/business/healthcare-pharmaceuticals/us-approves-two-gene-therapies-sickle-cell-disease-2023-12-08/

HERES WHY https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173389940

Always consult an Investment Professional, my posts are my own opinions, and not for investing decisions

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLUE News